Skip to content

A randomized controlled trial for prevention of acute exacerbation of stable Chronic Obstructive Pulmonary Disease with acupoint application of traditional Chinese medicine

A randomized controlled trial for prevention of acute exacerbation of stable Chronic Obstructive Pulmonary Disease with acupoint application of traditional Chinese medicine

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026564
Enrollment
Unknown
Registered
2019-10-14
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age ranged from 45 to 70 years, male or female. 2. In accordance with the COPD diagnostic criteria in the GOLD guidelines, and GOLD 2 to 3: FEV1/FVC <70% and 30% predicted value <= FEV1< 80% predicted value in 20 minutes after inhalation of salbutamol 400ug. 3. The patient is in a stable phase of COPD: the patient's symptoms such as cough, sputum, and shortness of breath are stable or mild, and the condition is basically restored to the state before acute exacerbation. 4. Patients with spleen-lung qi deficiency syndrome that meet the diagnostic criteria for common syndrome of traditional Chinese medicine. 5. Subjects volunteer to participate in the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Combined with chronic lung diseases requiring intervention or treatment such as bronchial asthma,interstitial lung disease, active tuberculosis, bronchiectasis. 2. Combined with severe primary diseases such as severe mental disorders, cardiovascular and cerebrovascular diseases, liver and kidney diseases, endocrine diseases, hematopoietic system diseases, malignant tumors, etc. 3. There were skin wounds, skin ulcers and skin infections on the application site. 4. Those who are allergic to traditional Chinese medicine, excipients or dressings for the project. 5. Patients with limited limb movements. 6. Women who are breastfeeding, pregnant or preparing for pregnancy. 7. Participated in other clinical studies in the past six months.

Design outcomes

Primary

MeasureTime frame
Number of exacerbations of COPD;

Secondary

MeasureTime frame
Pulmonary function measurement: FEV1 and FEV1/FVC change values;mMRC Questionnaire;CAT score;6-minute walk test;TCM syndrome score;

Countries

China

Contacts

Public ContactChuantao Zhang

Hospital of Chengdu University of Traditional Chinese Medicine

zhangchuantao@cdutcm.edu.cn+86 13568907974

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026